蔚蓝生物
(603739)
| 流通市值：39.47亿 | | | 总市值：39.47亿 |
| 流通股本：2.53亿 | | | 总股本：2.53亿 |
| 报告期 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 流动资产: | | | | |
| 货币资金 | 229,768,103.37 | 248,727,434.36 | 261,677,056.56 | 270,207,566.42 |
| 交易性金融资产 | 242,241,107.86 | 199,344,169.54 | 238,876,362.07 | 249,902,064.77 |
| 应收票据及应收账款 | 357,309,295.28 | 370,220,614.48 | 363,699,911.96 | 332,320,231.99 |
| 其中：应收票据 | 3,668,705.76 | 19,793,517.34 | 9,412,769.16 | 4,734,517.96 |
| 应收账款 | 353,640,589.52 | 350,427,097.14 | 354,287,142.8 | 327,585,714.03 |
| 应收款项融资 | 5,963,067.58 | 6,360,832.3 | 1,853,081.33 | 1,324,360.18 |
| 预付款项 | 18,950,155.75 | 13,893,639.38 | 21,519,722.29 | 20,317,297.58 |
| 其他应收款合计 | 29,133,503.05 | 28,681,828.45 | 31,378,896.43 | 35,503,824.77 |
| 其中:应收利息 | 35,353.5 | - | - | - |
| 存货 | 194,098,570.42 | 188,950,475.37 | 182,187,107.23 | 211,017,461.36 |
| 其他流动资产 | 24,097,417.89 | 13,015,733.92 | 17,660,627.3 | 18,625,333.72 |
| 流动资产合计 | 1,101,561,221.2 | 1,069,194,727.8 | 1,118,852,765.17 | 1,139,218,140.79 |
| 非流动资产: | | | | |
| 债权投资 | 14,000,000 | 14,000,000 | 5,000,000 | 5,000,000 |
| 长期股权投资 | 78,768,001.46 | 78,644,384.47 | 85,862,219.27 | 86,156,109.65 |
| 其他权益工具投资 | 5,996,056.64 | 5,996,056.64 | 3,926,402.61 | 3,926,402.61 |
| 固定资产 | 1,348,633,937.3 | 1,356,420,830.54 | 1,372,380,271.59 | 1,389,363,417.79 |
| 在建工程 | 177,856,184.32 | 203,810,847 | 103,764,871.97 | 94,325,740.17 |
| 无形资产 | 130,100,589.4 | 131,127,990.79 | 132,707,473.39 | 134,987,727.79 |
| 商誉 | 84,202,475.98 | 84,202,475.98 | 84,202,475.98 | 84,202,475.98 |
| 长期待摊费用 | 1,831,756.45 | 1,472,939.8 | 1,855,885.21 | 4,694,736.37 |
| 递延所得税资产 | 16,712,721.93 | 16,989,786.03 | 19,938,944.91 | 18,784,800.42 |
| 其他非流动资产 | 65,539,726.95 | 19,140,517.14 | 97,096,833.39 | 93,926,766.76 |
| 非流动资产合计 | 1,923,641,450.43 | 1,911,805,828.39 | 1,906,735,378.32 | 1,915,368,177.54 |
| 资产总计 | 3,025,202,671.63 | 2,981,000,556.19 | 3,025,588,143.49 | 3,054,586,318.33 |
| 流动负债: | | | | |
| 短期借款 | 642,866,997.78 | 581,633,655.82 | 612,220,000 | 662,160,000 |
| 应付票据及应付账款 | 200,763,616.7 | 224,558,653.92 | 211,229,555.53 | 210,982,760.23 |
| 其中：应付票据 | 13,236,054.45 | 12,833,364.45 | 9,362,310 | 4,939,600 |
| 应付账款 | 187,527,562.25 | 211,725,289.47 | 201,867,245.53 | 206,043,160.23 |
| 预收款项 | 18,885,787.01 | - | - | - |
| 合同负债 | 288,679.25 | 11,509,541.7 | 10,694,833.02 | 12,307,798.7 |
| 应付职工薪酬 | 18,031,318.89 | 37,448,333.07 | 18,091,307.26 | 20,924,568.25 |
| 应交税费 | 11,443,084.39 | 18,850,355.74 | 15,914,414.54 | 11,080,378.14 |
| 其他应付款合计 | 107,350,445.42 | 106,632,848.52 | 100,998,624.92 | 100,698,027.88 |
| 其中:应付利息 | - | - | 120,479.46 | 120,479.46 |
| 一年内到期的非流动负债 | 39,950,000 | 40,026,764.1 | 33,500,000 | 39,700,000 |
| 其他流动负债 | 17,488,409.08 | 10,789,141.94 | 10,239,751.67 | 10,626,600.89 |
| 流动负债合计 | 1,057,068,338.52 | 1,031,449,294.81 | 1,012,888,486.94 | 1,068,480,134.09 |
| 非流动负债: | | | | |
| 长期借款 | 25,703,526.81 | 13,956,437.56 | 104,950,000 | 98,500,000 |
| 长期应付款 | 152,000 | 152,000 | 152,000 | 152,000 |
| 递延收益 | 61,598,910.73 | 63,969,750.6 | 47,773,851.16 | 48,240,937.38 |
| 递延所得税负债 | 2,653,677.99 | 1,456,775.61 | 2,787,970.72 | 2,858,480.43 |
| 非流动负债合计 | 90,108,115.53 | 79,534,963.77 | 155,663,821.88 | 149,751,417.81 |
| 负债合计 | 1,147,176,454.05 | 1,110,984,258.58 | 1,168,552,308.82 | 1,218,231,551.9 |
| 所有者权益(或股东权益): | | | | |
| 实收资本(或股本) | 253,028,866 | 253,028,866 | 253,028,866 | 253,028,866 |
| 资本公积 | 702,876,454.13 | 702,898,795.16 | 714,923,077.47 | 713,940,319.91 |
| 其他综合收益 | -15,131,591.87 | -15,104,131.8 | -16,417,571.24 | -16,415,744.86 |
| 盈余公积 | 56,085,169.04 | 56,085,169.04 | 56,085,169.04 | 56,085,169.04 |
| 未分配利润 | 750,388,709.33 | 740,811,881.65 | 719,963,748.8 | 707,526,396.76 |
| 归属于母公司股东权益合计 | 1,747,247,606.63 | 1,737,720,580.05 | 1,727,583,290.07 | 1,714,165,006.85 |
| 少数股东权益 | 130,778,610.95 | 132,295,717.56 | 129,452,544.6 | 122,189,759.58 |
| 股东权益合计 | 1,878,026,217.58 | 1,870,016,297.61 | 1,857,035,834.67 | 1,836,354,766.43 |
| 负债和股东权益合计 | 3,025,202,671.63 | 2,981,000,556.19 | 3,025,588,143.49 | 3,054,586,318.33 |
| 公告日期 | 2025-04-26 | 2025-04-26 | 2024-10-29 | 2024-08-28 |
| 审计意见(境内) | | 标准无保留意见 | | |